All In Biotech

NDA 203510 · Paragon Bioteck

Phenylephrine Hydrochloride

Phenylephrine Hydrochloride · Ophthalmic

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 21, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

627

74 Phase 3, 25 recruiting

FAERS reports

3,598

3,445 serious, 1,812 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2023.

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is indicated to dilate the pupil. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil (1 ).

Mechanism: Phenylephrine is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels and the radial muscle of the iris.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PHENYLEPHRINE HYDROCHLORIDE · PHENYLEPHRINE HYDROCHLORIDE 2.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
  • PHENYLEPHRINE HYDROCHLORIDE · PHENYLEPHRINE HYDROCHLORIDE 10% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenylephrine" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,363
  • pemphigus1,074
  • joint swelling1,038
  • pain1,004
  • maternal exposure during pregnancy1,003
  • infusion related reaction996
  • glossodynia995
  • rheumatoid arthritis993
  • drug ineffective984
  • pericarditis983
  • systemic lupus erythematosus981
  • wound966

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200514
20066
200715
200815
20098
201043
201118
201252
201329
201416
201527
201628
201746
201846
201961
2020109
2021123
2022267
2023318
2024976
2025995
2026384

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,179 on PubMed

Sponsor: Paragon Bioteck

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.